{
  "events": [
    {
      "id": "EVT-2026-001",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on AQST-109 (epinephrine) for emergency treatment of allergic reactions",
      "date": "2026-01-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Standard review, NDA filing",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-002",
      "type": "pdufa",
      "ticker": "TVTX",
      "catalyst": "FDA decision on sparsentan for IgA nephropathy",
      "date": "2026-01-13",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review, NDA filing. Also has separate PDUFA for FSGS indication",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-003",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on Anaphylm (epinephrine sublingual film) for emergency treatment of anaphylaxis",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-004",
      "type": "pdufa",
      "ticker": "ASND",
      "catalyst": "FDA decision on TransCon CNP (navepegritide) for achondroplasia",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease treatment",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-005",
      "type": "pdufa",
      "ticker": "ALDX",
      "catalyst": "FDA decision on reproxalap for dry eye disease",
      "date": "2026-03-16",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Extended PDUFA date from original deadline",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-006",
      "type": "pdufa",
      "ticker": "BMY",
      "catalyst": "FDA decision on deucravacitinib (Sotyktu) for psoriatic arthritis",
      "date": "2026-03-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Label expansion for existing approved drug",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-007",
      "type": "pdufa",
      "ticker": "GSK",
      "catalyst": "FDA decision on linerixibat for cholestatic pruritus in primary biliary cholangitis",
      "date": "2026-03-24",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease indication",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-008",
      "type": "merger",
      "ticker": "AVDX",
      "catalyst": "Novartis acquisition of Avidity Biosciences expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$12B acquisition, $72/share (46% premium). Expected close in 2026, exact date TBD",
      "linked_idea": null,
      "source": "FiercePharma M&A coverage",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-009",
      "type": "merger",
      "ticker": "AKRO",
      "catalyst": "Novo Nordisk acquisition of Akero Therapeutics expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$4.7B acquisition, $54/share. MASH treatment focus. Expected close in 2026",
      "linked_idea": null,
      "source": "PwC M&A outlook",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-010",
      "type": "merger",
      "ticker": "CLRS",
      "catalyst": "Thermo Fisher acquisition of Clario expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$9.4B acquisition. Expected close early to mid-2026",
      "linked_idea": null,
      "source": "AllianceBernstein M&A analysis",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-011",
      "type": "merger",
      "ticker": "HALD",
      "catalyst": "Johnson & Johnson acquisition of Halda Therapeutics expected to close",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$3.05B acquisition. Expected close Q1 2026",
      "linked_idea": null,
      "source": "Expert Market Research",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-012",
      "type": "spinoff",
      "ticker": "CMCSA",
      "catalyst": "Comcast spin-off of Versant Media Group distribution",
      "date": "2026-01-02",
      "date_type": "hard",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Record date 12/16/2025, distribution 1/2/2026, regular-way trading begins 1/5/2026",
      "linked_idea": null,
      "source": "Comcast investor relations",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-013",
      "type": "spinoff",
      "ticker": "HON",
      "catalyst": "Honeywell separation of Aerospace and Automation divisions",
      "date": "2026-09-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Projected for second half of 2026. Two separate spinoffs planned",
      "linked_idea": null,
      "source": "StockSpinoffs.com",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-014",
      "type": "spinoff",
      "ticker": "MIDD",
      "catalyst": "Middleby Corporation spin-off of Industrial Processing Division",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Tax-free transaction. Expected completion by early 2026",
      "linked_idea": null,
      "source": "InsideArbitrage spinoff tracker",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-015",
      "type": "activist",
      "ticker": "NCPL",
      "catalyst": "Strategic EP LLC filed 13D pursuing strategic deal to maximize shareholder value",
      "date": "2025-12-02",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Recent 13D filing. Activist pursuing accretive transaction opportunities",
      "linked_idea": null,
      "source": "GlobeNewswire 13D filing announcement",
      "discovered_date": "2025-12-30"
    }
  ]
}
